ヒトパピローマウイルス市場：規模、セグメント別、シェア、法規制、償還、手技、2033年までの予測

ヒトパピローマウイルス（HPV）は、世界で最も一般的な性感染症（STI）として知られています。ヒトパピローマウイルス（HPV）検査は、主に子宮頸がんのスクリーニング、および/または子宮頸がんのリスクが高い可能性のある女性の特定に使用されます。HPVには、高リスク型HPVと低リスク型HPVを含む150種類以上の型があります。これらの型のうち、HPV-16型とHPV-18型が子宮頸がんの発症に最もよく関連しています。

HPV検出には、特異性と感度が高く、ハイスループット検査に適応できる核酸増幅（NAAT）検査が主流です。その他にも、in situハイブリダイゼーション検査、酵素免疫測定法（EIA）または酵素結合免疫吸着測定法（ELISA）キット、次世代シークエンシングアッセイなど、いくつかのHPV DNA検出法が報告されています。有利な政府政策、HPV感染の高い発生率、子宮頸がん検診の啓蒙計画の高まりなどの要因が、予測期間中にHPV検査市場全体を牽引すると予想されます。性器疣贅は、HPV-6やHPV-11などの非発がん性HPV株によって引き起こされることが多いです。

HPV検査には、ヒトパピローマウイルス（HPV）核酸増幅検査（NAAT）およびその他のヒトパピローマウイルス（HPV）検査キットが含まれます。

当レポートは、世界のヒトパピローマウイルス市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されているヒトパピローマウイルスと競合情勢

• 主要な業界動向の洞察
• ヒトパピローマウイルスのセグメント別総市場収益と2015年～2033年の市場展望
• 個数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• ヒトパピローマウイルス市場のSWOT分析
• ヒトパピローマウイルス市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

Abstract

Human Papilloma Virus Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Human Papilloma Virus Tests market for the year 2020 and beyond. Human papillomavirus (HPV) is known as the most common sexually transmitted infection (STI) in the world. Human Papillomavirus (HPV) Tests are primarily used to screen for cervical cancer and/or identify women who may be at increased risk of cervical cancer. There are over 150 types of HPV including both high-risk HPV and low-risk HPV. Out of these strains, types HPV-16 and HPV-18 are most commonly associated with development of cervical cancer.

The predominant devices used for HPV detection are Nucleic-acid amplification (NAAT) tests, owing to their high specificity and sensitivity as well as their ability to be adapted for high-throughput testing. Several other HPV DNA detection methods have also been described including in situ hybridization tests, Enzyme Immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA) kits, and next generation sequencing assays. Factors like favorable government policies, high occurrence rate of HPV infections, and growing cervical cancer screening awareness plans are expected to drive the overall HPV testing market during the forecast period. Genital warts are often caused by non-oncogenic strains of HPV, such as HPV-6 and HPV-11.

The HPV tests includes Human Papilloma Virus (HPV) Nucleic Acid Amplification Tests (NAATs) and Other Human Papilloma Virus (HPV) Test Kits.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Human Papilloma Virus Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Human Papilloma Virus Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Human Papilloma Virus market.
• Competitive dynamics insights and trends provided for Human Papilloma Virus market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Hologic Inc, Qiagen NV, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Biocare Medical LLC, Enzo Biochem Inc, Danaher Corp, Thermo Fisher Scientific Inc and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

• CMO executives who must have deep understanding of the Human Papilloma Virus (HPV) Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

• Understand the impact of COVID-19 on Human Papilloma Virus (HPV) Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Human Papilloma Virus (HPV) Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Human Papilloma Virus (HPV) Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Human Papilloma Virus (HPV) Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.